Dengue vaccines: where are we now and where we are going?

Affiliations

¹ Laboratory of Infectious Agents and Vectors, Center of Biological Sciences and Health, Federal University of Western Bahia, Barreiras, CEP 47810-047, BA, Brazil. Electronic address: jaime.amorim@ufob.edu.br.
² Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.

Comment

Jaime Henrique Amorim et al. Lancet Infect Dis. 2022 Jun.

. 2022 Jun;22(6):756-757.

doi: 10.1016/S1473-3099(21)00753-2. Epub 2022 Mar 29.

¹ Laboratory of Infectious Agents and Vectors, Center of Biological Sciences and Health, Federal University of Western Bahia, Barreiras, CEP 47810-047, BA, Brazil. Electronic address: jaime.amorim@ufob.edu.br.
² Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.

No abstract available

Conflict of interest statement

We declare no competing interests.

Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
Coronel-Martinez DL, Park J, López-Medina E, Capeding MR, Bonfanti AAC, Montalbán MC, Ramírez I, Gonzales MLA, Zambrano B, Dayan G, Chen Z, Wang H, Bonaparte M, Rojas A, Ramírez JC, Verdan MA, Noriega F. Coronel-Martinez DL, et al. Lancet Infect Dis. 2022 Jun;22(6):901-911. doi: 10.1016/S1473-3099(21)00706-4. Epub 2022 Mar 29. Lancet Infect Dis. 2022. PMID: 35364022 Clinical Trial.